South Korea
· Delayed Price · Currency is KRW Prestige BioPharma Statistics
Total Valuation
Prestige BioPharma has a market cap or net worth of KRW 173.08 billion. The enterprise value is 168.13 billion.
| Market Cap | 173.08B |
| Enterprise Value | 168.13B |
Important Dates
The last earnings date was Friday, November 29, 2024.
| Earnings Date | Nov 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Prestige BioPharma has 12.02 million shares outstanding. The number of shares has increased by 0.42% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 12.02M |
| Shares Change (YoY) | +0.42% |
| Shares Change (QoQ) | +1.21% |
| Owned by Insiders (%) | 30.40% |
| Owned by Institutions (%) | 0.10% |
| Float | 3.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.32 |
| P/TBV Ratio | 0.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.68 |
| EV / Sales | 59.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.99 |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of 0.23.
| Current Ratio | 1.41 |
| Quick Ratio | 1.28 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.31 |
| Interest Coverage | -8.18 |
Financial Efficiency
Return on equity (ROE) is -9.51% and return on invested capital (ROIC) is -6.18%.
| Return on Equity (ROE) | -9.51% |
| Return on Assets (ROA) | -5.20% |
| Return on Capital (ROIC) | -6.18% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.09 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.22% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +56.22% |
| 50-Day Moving Average | 15,895.00 |
| 200-Day Moving Average | 11,854.70 |
| Relative Strength Index (RSI) | 44.19 |
| Average Volume (20 Days) | 118,586 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Prestige BioPharma had revenue of KRW 2.84 billion and -29.59 billion in losses. Loss per share was -490.70.
| Revenue | 2.84B |
| Gross Profit | 1.63B |
| Operating Income | -60.57B |
| Pretax Income | -48.44B |
| Net Income | -29.59B |
| EBITDA | -43.14B |
| EBIT | -60.57B |
| Loss Per Share | -490.70 |
Balance Sheet
The company has 225.76 billion in cash and 110.61 billion in debt, giving a net cash position of 115.15 billion or 9,580.78 per share.
| Cash & Cash Equivalents | 225.76B |
| Total Debt | 110.61B |
| Net Cash | 115.15B |
| Net Cash Per Share | 9,580.78 |
| Equity (Book Value) | 488.55B |
| Book Value Per Share | 6,215.65 |
| Working Capital | 72.15B |
Cash Flow
In the last 12 months, operating cash flow was -55.55 billion and capital expenditures -28.91 billion, giving a free cash flow of -84.46 billion.
| Operating Cash Flow | -55.55B |
| Capital Expenditures | -28.91B |
| Free Cash Flow | -84.46B |
| FCF Per Share | -7,026.94 |
Margins
| Gross Margin | 57.17% |
| Operating Margin | -2,130.05% |
| Pretax Margin | -1,703.66% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Prestige BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.42% |
| Shareholder Yield | -0.42% |
| Earnings Yield | -3.41% |
| FCF Yield | -48.80% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Prestige BioPharma has an Altman Z-Score of -0.4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.4 |
| Piotroski F-Score | n/a |